Joana Amado

Mrs. Joana Amado


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JAJéssica Antunes
Jéssica Antunes
JAJoana Amado
Joana Amado
Francisco VeigaFrancisco Veiga
Francisco Veiga
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
PPPatrícia C. Pires
Patrícia C. Pires
Depression and anxiety are high incidence and debilitating psychiatric disorders, usually treated by antidepressant or anxiolytic drug administration, respectively. Nevertheless, treatment is usually given through the oral route, but the low permeability of the blood–brain barrier reduces the amount of drug that will be able to reach it, thus consequently reducing the therapeutic efficacy. Which is why it is imperative to find new solutions to make these treatments more effective, safer, and faster. To overcome this obstacle, three main strategies have been used to improve brain drug targeting: the intranasal route of administration, which allows the drug to be directly transported to the brain by neuronal pathways, bypassing the blood–brain barrier and avoiding the hepatic and gastrointestinal metabolism; the use of nanosystems for drug encapsulation, including polymeric and lipidic nanoparticles, nanometric emulsions, and nanogels; and drug molecule functionalization by ligand attachment, such as peptides and polymers. Pharmacokinetic and pharmacodynamic in vivo studies’ results have shown that intranasal administration can be more efficient in brain targeting than other administration routes, and that the use of nanoformulations and drug functionalization can be quite advantageous in increasing brain–drug bioavailability. These strategies could be the key to future improved therapies for depressive and anxiety disorders.

1 November 2022 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
JAJoana Amado
Joana Amado
PPPatrícia C. Pires
Patrícia C. Pires
Francisco VeigaFrancisco Veiga
Francisco Veiga
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
Melanoma is one of the most dangerous skin cancers, with a high mortality rate and an incidence that has increased radically in the past few years. This has led to a huge demand for new more effective forms of treatment. Nanoemulsions have been investigated as potential drug delivery vehicles to target cancer cells, since they are a promising alternative to increase the solubility and the skin permeation and retention of hydrophobic drugs. The purpose of this work was to incorporate miconazole, a hydrophobic antifungal drug with potential anticancer activity, into an oil-in-water (O/W) nanoemulsion for topical administration for the treatment of melanoma. Seventeen O/W nanoemulsions were prepared via spontaneous emulsification. The preconcentrate was composed of Plurol® Diisostearique, Transcutol® HP and Kolliphor® RH 40, while the aqueous phase was water. A visual examination was performed to confirm the absence of phase separation and heterogeneity. Analysis using dynamic light scattering (Zetasizer Nano ZS apparatus, Malvern, UK) followed to determine the droplet size and polydispersity index (PDI). Nanoemulsions with a PDI below 0.300 and a droplet size between 100 and 200 nm were selected for solubility assays. After drug incorporation, at 5 mg/mL, only one out of the seventeen nanoemulsions showed characteristics within the intended parameters. In conclusion, this study showed that the incorporation of miconazole in nanoemulsions allows us to greatly increase its solubility when compared to water (up to 6550 times). Future studies will include the determination of viscosity, stability, in vitro drug release, ex vivo drug permeation and in vitro cytotoxicity in melanoma cells.